Literature DB >> 2997604

Peripheral neuropathies associated with monoclonal proteins: a clinical review.

J J Kelly.   

Abstract

Over the last decade, the increasing use of serum and urine protein electrophoretic screening of patients with idiopathic peripheral neuropathy has led to greater recognition of peripheral neuropathy syndromes that are associated with monoclonal proteins and plasma cell dycrasias. After careful evaluation, most of these patients have benign monoclonal gammopathy, followed in frequency by primary systemic amyloidosis and osteosclerotic myeloma, with occasional cases associated with osteolytic multiple myeloma, Waldenstrom's macroglobulinemia, gamma heavy chain disease, and other rare disorders. Several of these syndromes have distinctive presentations and are recognizable clinically, whereas others (especially multiple myeloma neuropathy) are diverse clinically and are not clearly distinguishable from other chronic neuropathies. The discovery of IgM-kappa monoclonal proteins directed at myelin antigens in some patients with benign monoclonal gammopathy and the delineation of the syndrome of neuropathy and multiorgan involvement in osteosclerotic myeloma are important developments which may shed light on the mechanism of the remote effects of malignancies on the nervous system.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2997604     DOI: 10.1002/mus.880080210

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  13 in total

1.  CD5 expression on B cells may be an activation marker for secretion of anti-myelin antibodies in patients with polyneuropathy associated with monoclonal gammopathy.

Authors:  C Ekerfelt; J Ernerudh; G Solders; M Vrethem
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

2.  Lymphoma, paraproteinaemia, and neuropathy.

Authors:  J H Wokke; J H Morris; M Donaghy
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

3.  Retrospective chart review of duloxetine and pregabalin in the treatment of painful neuropathy.

Authors:  Manoj Mittal; Mamatha Pasnoor; Reddiah B Mummaneni; Saud Khan; April McVey; David Saperstein; Laura Herbelin; Larry Ridings; Yunxia Wang; Mazen M Dimachkie; Richard J Barohn
Journal:  Int J Neurosci       Date:  2011-06-15       Impact factor: 2.292

4.  Binding of swine IgM immunoglobulins to peripheral nerve myelin sheaths in electron microscopic immunocytochemistry.

Authors:  C Sommer; J M Schröder
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

5.  Systemic lupus erythematosus presenting with neurological disorders.

Authors:  M R Tola; E Granieri; L Caniatti; E Paolino; C Monetti; L Dovigo; R Scolozzi; P De Bastiani; M Carreras
Journal:  J Neurol       Date:  1992-02       Impact factor: 4.849

6.  Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients.

Authors:  T Maisonobe; B Chassande; M Vérin; M Jouni; J M Léger; P Bouche
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-07       Impact factor: 10.154

7.  Axonal neuropathy associated with monoclonal gammopathy of undetermined significance.

Authors:  K C Gorson; A H Ropper
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-08       Impact factor: 10.154

Review 8.  Peripheral neuropathies in rheumatic disease--a guide to diagnosis.

Authors:  Jean-Michel Vallat; Magalie Rabin; Laurent Magy
Journal:  Nat Rev Rheumatol       Date:  2012-08-21       Impact factor: 20.543

9.  Immunochemical and clinical effects of immunosuppressive treatment in monoclonal IgM neuropathy.

Authors:  J H Ernerudh; M Vrethem; O Andersen; C Lindberg; G Berlin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

10.  IgM monoclonal gammopathy and neuropathy in two siblings.

Authors:  T S Jensen; H D Schrøder; V Jønsson; J Ernerudh; B Stigsby; Z Kamieniecka; E Hippe; W Trojaborg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-10       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.